MYO1A

Across TCGA pan-cancer cohorts, MYO1A mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MYO1A data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MYO1A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MYO1A expression acts as an unfavorable survival marker, although some lineages such as PDAC and COAD show a favorable association.

PDAC, COAD, and LUAD are the cancer types where MYO1A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.565	0.287	<.001	95	view →
COAD	DFS	Tertile	All	1.000	0.828	.014	36	view →
LUAD	DFS	Median	II,III,IV	0.667	0.990	.006	11	view →
CCRCC	DFS	Median	II,III,IV	0.177	1.000	.014	7	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MYO1A–PDAC (DFS)

Open the PDAC breakdown →